News
Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world. Collectively known as GLP-1 agonists, ...
Learn how semaglutide boosts health but also increases health care spending for patients. Keep reading to explore more.
Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...
An estimated 2·1 billion adults worldwide are affected by overweight and obesity, a figure projected to reach 3·8 billion by ...
Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...
The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...
As semaglutide sees a surge in use, new research raises questions about the medication’s effects on muscle health. A study published Aug. 5 in Cell Metabolism and led by researchers at Salt Lake ...
A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.
Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.
2d
TipRanks on MSNSihuan Pharmaceutical’s Semaglutide Injection NDA Accepted by NMPA
Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group announced that its subsidiary, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results